JP7725042B2 - 造血器腫瘍治療用組成物、造血器腫瘍治療用医薬、及び造血器腫瘍における癌化細胞の増殖抑制用組成物 - Google Patents

造血器腫瘍治療用組成物、造血器腫瘍治療用医薬、及び造血器腫瘍における癌化細胞の増殖抑制用組成物

Info

Publication number
JP7725042B2
JP7725042B2 JP2025515487A JP2025515487A JP7725042B2 JP 7725042 B2 JP7725042 B2 JP 7725042B2 JP 2025515487 A JP2025515487 A JP 2025515487A JP 2025515487 A JP2025515487 A JP 2025515487A JP 7725042 B2 JP7725042 B2 JP 7725042B2
Authority
JP
Japan
Prior art keywords
nucleic acid
cationic
group
hematopoietic tumors
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2025515487A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024242065A5 (https=
JPWO2024242065A1 (https=
Inventor
寛子 宮本
幸夫 北出
幸博 赤尾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency filed Critical Japan Science and Technology Agency
Publication of JPWO2024242065A1 publication Critical patent/JPWO2024242065A1/ja
Publication of JPWO2024242065A5 publication Critical patent/JPWO2024242065A5/ja
Application granted granted Critical
Publication of JP7725042B2 publication Critical patent/JP7725042B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2025515487A 2023-05-19 2024-05-17 造血器腫瘍治療用組成物、造血器腫瘍治療用医薬、及び造血器腫瘍における癌化細胞の増殖抑制用組成物 Active JP7725042B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023082728 2023-05-19
JP2023082728 2023-05-19
PCT/JP2024/018410 WO2024242065A1 (ja) 2023-05-19 2024-05-17 核酸送達用構造体の造血器腫瘍の治療への使用

Publications (3)

Publication Number Publication Date
JPWO2024242065A1 JPWO2024242065A1 (https=) 2024-11-28
JPWO2024242065A5 JPWO2024242065A5 (https=) 2025-06-03
JP7725042B2 true JP7725042B2 (ja) 2025-08-19

Family

ID=93589879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025515487A Active JP7725042B2 (ja) 2023-05-19 2024-05-17 造血器腫瘍治療用組成物、造血器腫瘍治療用医薬、及び造血器腫瘍における癌化細胞の増殖抑制用組成物

Country Status (5)

Country Link
EP (1) EP4714453A1 (https=)
JP (1) JP7725042B2 (https=)
CN (1) CN121175056A (https=)
AU (1) AU2024276929A1 (https=)
WO (1) WO2024242065A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022230990A1 (ja) 2021-04-28 2022-11-03 国立研究開発法人科学技術振興機構 人工核酸及びそれを用いた核酸の送達方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10487103B2 (en) 2015-03-24 2019-11-26 Gifu University Oligonucleotide derivative, oligonucleotide construct using the same, and methods for producing them
WO2017179660A1 (ja) 2016-04-14 2017-10-19 国立大学法人岐阜大学 マイクロｒｎａ－１４３誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022230990A1 (ja) 2021-04-28 2022-11-03 国立研究開発法人科学技術振興機構 人工核酸及びそれを用いた核酸の送達方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
平島 一輝，miR-143-ナノ脂質抱合粒子を用いたKRAS変異多発性骨髄腫治療法の開発，科学研究費助成事業 研究成果報告書，課題番号：２０Ｋ１６２１６，2022年06月20日

Also Published As

Publication number Publication date
EP4714453A1 (en) 2026-03-25
AU2024276929A1 (en) 2025-12-18
WO2024242065A1 (ja) 2024-11-28
CN121175056A (zh) 2025-12-19
JPWO2024242065A1 (https=) 2024-11-28

Similar Documents

Publication Publication Date Title
ES2899043T3 (es) Novedosos conjugados de oligonucleótidos y su uso
SG185295A1 (en) Lipid-modified double-stranded rna having potent rna interference effect
EP4331617A1 (en) Artificial nucleic acid and nucleic acid delivering method using same
JP7725042B2 (ja) 造血器腫瘍治療用組成物、造血器腫瘍治療用医薬、及び造血器腫瘍における癌化細胞の増殖抑制用組成物
JP6492014B2 (ja) 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
CN110960683B (zh) 含甲氨蝶呤的药物、其制备方法、药物组合物及其应用
CN111150852B (zh) 含顺铂的药物、其制备方法、药物组合物及其应用
CN111096965B (zh) 含双氢青蒿素的药物、其制备方法、药物组合物及其应用
CN110960530B (zh) 含他克林的药物、其制备方法、药物组合物及其应用
CN110960534B (zh) 含五氟尿嘧啶的药物、其制备方法、药物组合物及其应用
CN111053765B (zh) 含紫杉醇的药物、其制备方法、药物组合物及应用
CN110960691B (zh) 含吉西他滨的药物、其制备方法、药物组合物及应用
WO2025225509A1 (ja) 核酸送達用構造体、核酸送達用構造体の製造方法、及び医薬
CN117295528A (zh) 人工核酸以及使用该人工核酸的核酸递送方法
CN110960684B (zh) 含10-羟基喜树碱的药物、其制备方法、药物组合物及其应用
CN111053914B (zh) 含米托蒽醌的药物、其制备方法、药物组合物及其应用
CN110960536B (zh) 含阿司匹林的药物、其制备方法、药物组合物及应用
CN110960689B (zh) 含柔红霉素的药物、其制备方法、药物组合物及其应用
CN110960690B (zh) 含表柔比星的药物、其制备方法、药物组合物及其应用
CN111053919B (zh) 含伊达比星的药物、其制备方法、药物组合物及其应用
CN111166894B (zh) 含多西他赛的药物、其制备方法、药物组合物及应用
JPWO2024242065A5 (https=)
CN110960542A (zh) 含吡柔比星的药物、其制备方法、药物组合物及其应用
CN111068065A (zh) 含奥沙利铂的药物、其制备方法、药物组合物及其应用
Kiviniemi Studies on Intrachain Conjugation, Hybridization and Invasion of Oligonucleotides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250312

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250312

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250711

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250729

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250729

R150 Certificate of patent or registration of utility model

Ref document number: 7725042

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150